FindTrial
Sign In

Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease

Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease - Switch trial from IR to ER of Pramipexole

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006521
Enrollment
30
Registered
2011-10-11
Start date
2011-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Rapid switch of Pramipexole ER (once in a day) which is same dose as IR. The period of administration is 8 weeks.

Sponsors

Department of Neurology, Juntendo University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Parkinson's disease patients with nocturnal and early morning symptoms. Patients doesn't take dopamine agonist except Pramipexole. Yahr stage is 2-4 at on-phase.

Exclusion criteria

Exclusion criteria: Patients take other dopamin agonist have psychiatric symptoms have hypotension have cardiac, renal, and hepatic disease are pregnant take the medicine of other clinical trial

Design outcomes

Primary

MeasureTime frame
Preference and convenience for ER Nocturnal and early morning symptoms UPDRS part2 and part3 score—

Countries

Japan

Contacts

Public ContactMasashi Takanashi

Juntendo University Department of Neurology

nassy-m@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026